Key clinical point:
Major finding: The overall response rate was 53%.
Study details: A phase 1 trial involving 30 patients.
Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.
Source: Advani A et al. ASH 2017, Abstract 150.
Advani A et al. ASH 2017, Abstract 150.
This Week's Must Reads
Screening for Syphilis Infection in Pregnant Women, JAMA; 2018 Sep 4; US Preventive Services Task Force
Treatment Intensification Guidelines for T2D , Ann Intern Med; ePub 2018 Sep 4; Roglic, et al
Immediate vs Gradual Nicotine Reduction in Cigarettes, JAMA; ePub 2018 Sep 4; Hatsukami, et al
Prevalence of Diabetes Among US Adults, BMJ; ePub 2018 Aug 27; Xu, Liu, et al
Effect of Fish Oil Supplementation in Pregnancy, BMJ; ePub 2018 Sep 4; Vinding, Stokholm, et al
Must Reads in Oncology
Trends in HPV-Associated Cancers in the US, MMWR; 2018 Aug 24; Van Dyne, Henley, et al
Screening for Cervical Cancer in Primary Care, JAMA; 2018 Aug 21; Kim, Burger, et al
Endometrial Ca Risk with Postmenopausal Bleeding, JAMA Intern Med; ePub 2018 Aug 6; Clarke, et al
Can Mailed FIT Outreach Increase CRC Screening?, JAMA Intern Med; ePub 2018 Aug 6; Coronado, et al
Mortality Due to Cirrhosis & Liver Cancer in the US, BMJ; ePub 2018 Jul 18; Tapper, Parikh